Roy D. Baynes, Director at Travere Therapeutics, Inc. (TVTX), sold 10,000 shares at $22.00 ($220K) on 2025-02-06, disclosed to the SEC on 2025-02-10.
Scheduled sale ($220k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| TVTX | SELL | 2026-05-04 | $431K | — | Filing → |
| TVTX | SELL | 2026-04-16 | $1.4M | — | Filing → |
| TVTX | SELL | 2026-04-07 | $330K | — | Filing → |